Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

Oncos Therapeutics commences clinical study with oncolytic viruses

Oncos Therapeutics today announced the successful initiation of its Phase I clinical study of CGTG-102, an oncolytic adenovirus suggested as a potential new treatment for many types of solid tumors.

29 May 2012

Cardiac ischemia plays an important role in adenovector gene transfection in mammalian hearts

Cardium Therapeutics today announced a late-breaking poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting being held May 16-19, 2012 at the Pennsylvania Convention Center in Philadelphia, PA.

17 May 2012

Certain males at higher risk of infection after receiving experimental HIV vaccine

A long-term follow-up analysis of participants in the Step Study, an international HIV-vaccine trial, has confirmed that certain subgroups of male study participants were at higher risk of becoming infected after receiving the experimental vaccine compared to those who received a placebo.

8 May 2012

PloS ONE publishes research on GenVec's new vaccine vectors

GenVec, Inc. announced publication of research on GenVec's new vaccine vectors. These vectors circumvent neutralizing antibodies in order to generate the desired immunologic response.

7 Apr 2012

Abbott receives CE Marking for PLEX-ID instrument and assays

Abbott announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput PLEX-ID instrument, along with three assays for use on the system: PLEX-ID Viral IC Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu.

31 Mar 2012

GenVec announces data from respiratory syncytial virus vaccine program

GenVec, Inc. (Nasdaq: GNVC) announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the "Keystone Symposium on Viral Immunity and Host Gene Influence", which is taking place in Keystone, Colorado from March 21-26, 2012.

26 Mar 2012

Positive data from Chimerix CMX001 Phase 2 study on CMV disease

Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.

6 Feb 2012

Positive results from Chimerix CMX001 study for CMV in hematopoietic stem cell transplant recipients

6 Feb 2012

Mass. Eye and Ear cornea specialist wins RPB Senior Scientific Investigator Award

Research to Prevent Blindness (RPB) has granted Massachusetts Eye and Ear Infirmary cornea specialist James Chodosh, M.D., M.P.H., a $150,000 Senior Scientific Investigator Award. RPB Senior Scientific Investigator Awards support nationally recognized scientists conducting eye research at medical institutions in the United States.

27 Jan 2012

Critical considerations for adenovirus-based HIV vaccine trials

A clinical trial testing a candidate HIV vaccine known as the STEP study was halted in September 2007 after interim analysis indicated that the vaccine did not work. Moreover, subsequent analyses indicated that the vaccine made some individuals more susceptible to HIV, in particular individuals who had pre-existing immune effectors (antibodies) that recognized a component of the vaccine (adenovirus serotype 5 [Ad5]).

28 Dec 2011

New gene editing technique can heal sickle cell patients with their own cells

Researchers at the Salk Institute for Biological Studies have developed a way to use patients' own cells to potentially cure sickle cell disease and many other disorders caused by mutations in a gene that helps produce blood hemoglobin.

8 Dec 2011

Gene-therapy trial to restore hearing in deaf mice

Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.

22 Nov 2011

Thyroid researcher to receive ATA's John B. Stanbury Pathophysiology Medal

Each year, the American Thyroid Association (ATA) recognizes the outstanding research contributions of one of its members to a greater understanding of thyroid physiology or the pathophysiology of thyroid disease, with its presentation of the John B. Stanbury Pathophysiology Medal at its Annual Meeting.

29 Oct 2011

New insights into how adenovirus triggers an immune response

A Loyola University Chicago Stritch School of Medicine study could lead to improved gene therapies for conditions such as heart disease and cancer as well as more effective vaccines for tuberculosis, malaria and other diseases.

13 Oct 2011

Virus DNA uncoated with aid of host cell

They have been around since the dawn of time and are a model of evolutionary success: viruses. Viruses are extremely adaptable but they have a problem: They cannot reproduce, so they smuggle their genes into suitable host cells. In the case of some viruses, the viral DNA has to enter the cell nucleus to reproduce. This has been known for almost 50 years.

4 Oct 2011

MRI-based technique allows researchers to follow neural stem cells in vivo

Carnegie Mellon University biologists have developed an MRI-based technique that allows researchers to non-invasively follow neural stem cells in vivo.

30 Sep 2011

BARDA awards Vaxin $21.7M contract to accelerate development of novel anthrax vaccine

Vaxin Inc., a clinical stage vaccine development company, today announced that it has been awarded a contract valued at up to $21.7 million by the Office of Biomedical Advanced Research and Development Authority (BARDA) for pre-clinical assessment, final manufacturing process development and the supply of clinical materials to support an IND filing and first-in-man dose ranging study of the company's proprietary anthrax vaccine, AdVAV.

17 Sep 2011

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.

14 Sep 2011

Novel studies explore new targets to prevent spread of breast cancer

Research into new methods to prevent and slow metastatic breast cancer will be presented this week at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program.

5 Aug 2011

Insect virus holds key to safer stem cell therapy: Singapore scientists

The future of regenerative medicine lies in harnessing the potential of the human body to renew and repair itself. Now, scientists at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have developed a new genetic engineering technique that promises safer stem cell therapy for cancer patients. Using an insect virus, the team of researchers successfully inserted a therapeutic gene into a safe site in the DNA of human embryonic stem cells without compromising the functionality of the engineered cells.

28 Jul 2011